



XOMA Corporation
 Investor Relations Department
 2910 Seventh St.
 Berkeley, CA 94710
 United States

[Visit IR website](#)

[Sign-up for email alerts](#)

NASDAQ: XOMA ¹

| | |
|-------------------|-----------------------------|
| Last Trade: | 22.47 |
| Trade Time: | 10:59 AM ET Oct 17, 2017 |
| Change: | 0.43 (1.951%) |
| Day Range | 22.29 - 22.75 |
| 52-Week Range | 3.96 - 23.58 |
| Volume | 28,115 |
| Market Cap. (\$M) | 170.772 |
| Shares Out (M) | 7.600 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

XOMA Corporation (Nasdaq: XOMA) is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for serious unmet medical needs. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than \$1 billion in annual sales and for which XOMA received substantial royalties. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government, and has licensed certain of its fundamental technologies to more than 60 companies.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 4, 2017
[XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries](#)
- Sep 19, 2017
[XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 11, 2017
[XOMA Earns \\$3 Million Milestone Payment from its License Agreement with Nanotherapeutics](#)
- Sep 6, 2017
[XOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference](#)
- Aug 25, 2017
[XOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

- Mar 16, 2017
[Annual Report \(10-K\)](#)
- Apr 5, 2017
[Definitive Proxy Statement](#)
- Aug 8, 2017
[Quarterly Report \(10-Q\)](#)
- May 9, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016
[Quarterly Report \(10-Q\)](#)